|
| 36454580 | Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial. | JAMA Oncol | 2023 |
| 35941343 | Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy. | Ann Surg Oncol | 2023 |
| 37923752 | Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. | Nat Commun | 2023 |
| 37652539 | Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial). | J Nucl Med | 2023 |
| 37801674 | Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3-Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epidermal Growth Factor Receptor 3-Expressing Metastatic Breast Cancer: A Multicenter, Phase I/II Tria | | 2023 |
| 37693537 | Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy. | bioRxiv | 2023 |
| 38047578 | Axillary Nodal Response to Neoadjuvant T-DM1 Combined with Pertuzumab in a Prospective Phase II Multi-Institution Clinical Trial. | | 2023 |
| 36585450 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | Nat Cancer | 2023 |
| 37086745 | Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. | | 2023 |
| 36892268 | ER+, HER2- advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. | | 2023 |
| 37268724 | Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results. | Nat Med | 2023 |
| 36945501 | Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030. | medRxiv | 2023 |
| 36564285 | Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]. | Ann Oncol | 2023 |
| 37195235 | A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer. | Clin Cancer Res | 2023 |
| 37194964 | Impact of Neoadjuvant Paclitaxel/Trastuzumab/Pertuzumab on Breast Tumor Downsizing for Patients with HER2+ Breast Cancer: Single-Arm Prospective Clinical Trial. | J Am Coll Surg | 2023 |
| 36858723 | Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. | Lancet Oncol | 2023 |
| 37364233 | Genomics of <i>ERBB2</i>-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab. | JCO Precis Oncol | 2023 |
| 36602784 | Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. | JAMA Oncol | 2023 |
| 37103927 | Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. | JAMA Oncol | 2023 |
| 37101291 | Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers. | | 2023 |
| 35138919 | Phase II Study of Taselisib in <i>PIK3CA</i>-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. | JCO Precis Oncol | 2022 |
| 35658506 | Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. | J Clin Oncol | 2022 |
| 35640077 | Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Guideline Update. | J Clin Oncol | 2022 |
| 35640075 | Management of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. | J Clin Oncol | 2022 |
| 36215125 | Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer. | Clin Cancer Res | 2022 |
| 35538105 | A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. | NPJ Breast Cancer | 2022 |
| 36450763 | Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). | NPJ Breast Cancer | 2022 |
| 36252998 | Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer. | J Immunother Cancer | 2022 |
| 34990776 | Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. | Int J Radiat Oncol Biol Phys | 2022 |
| 35301450 | Massively parallel enrichment of low-frequency alleles enables duplex sequencing at low depth. | Nat Biomed Eng | 2022 |
| 35313167 | Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. | Eur J Cancer | 2022 |
| 35173164 | Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. | NPJ Breast Cancer | 2022 |
| 35024766 | Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review. | JAMA Oncol | 2022 |
| 34954044 | Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. | Ann Oncol | 2022 |
| 34890214 | Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study. | J Clin Oncol | 2022 |
| 34942341 | Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? | Ann Oncol | 2022 |
| 34636255 | Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1Â + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. | Future Oncol | 2021 |
| 33591468 | The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+â¿¿and androgen receptor-positive metastatic or locally advanced breast cancer. | Breast Cancer Res Treat | 2021 |
| 34077270 | Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. | J Clin Oncol | 2021 |
| 34120223 | Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). | Breast Cancer Res Treat | 2021 |
| 33539215 | Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up. | Journal of Clinical Oncology | 2021 |
| 34117261 | Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancer patients. | npj Breast Cancer | 2021 |
| 33999652 | Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. | J Clin Oncol | 2021 |
| 33997789 | CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. | Nat Cancer | 2021 |
| 33941592 | Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab. | Cancer Discov | 2021 |
| 33886505 | The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer. | JCI Insight | 2021 |
| 33980863 | FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. | NPJ Breast Cancer | 2021 |
| 34302589 | A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer. | Breast Cancer Res Treat | 2021 |
| 33186740 | Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial. | Annals of Oncology | 2021 |
| 33293374 | Genomic Characterization of <i>de novo</i> Metastatic Breast Cancer. | Clin Cancer Res | 2021 |